This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Conference Highlights
AUA 2024
AUA 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
Testicular and Penile Cancer
Press Releases
Sexual Dysfunction
Endourology and Stone Disease
Lower Urinary Tract Conditions
AUA 2024 Bladder Cancer
Viewing 1-20 of 53 articles
AUA 2024: Back to Medical School: Immunology in NMIBC and Neoadjuvant MIBC for the Urologist
AUA 2024: Panel Discussion: Interstitial Cystitis/ Systemic Therapy for Bladder Pain Syndrome: Which Patient and Which Therapy?
AUA 2024: Can I use Markers and Imaging to Avoid Local Consolidation for Patient who has cT0 stage after Neoadjuvant Chemo or IO?
AUA 2024: BCG Unresponsive Disease: How Much Risk can my Patient Tolerate?
AUA 2024: Very High Risk NMIBC with Variant Histology
AUA 2024: Patient-Reported Toxicity During Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
AUA 2024: Management of Recurrent Low Grade Intermediate Risk Bladder Tumors
AUA 2024: How to Incorporate Enfortumab With or Without Pembrolizumab Into Your Practice
AUA 2024: First Line Therapy for Locally Advanced/Metastatic UC in 2024
AUA 2024: Can we Settle the Debate on PLND in Radical Cystectomy?
AUA 2024: Role of Urinary Markers in Surveillance of NMIBC Patients
AUA 2024: Elucidating the Response Rates to Continued Bacillus Calmette-Guerin (BCG) in Patients with BCG Exposed Bladder Cancer: Implications for Clinical Trial Design
AUA 2024: Diagnostic Performance of Fluorescence Cystoscopy Using Oral 5-Aminolevulinic Acid in Transurethral Resection of Bladder Tumor After BCG Treatment
AUA 2024: Photodynamic Diagnosis Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study
AUA 2024: Optimal TURBT: Do Skilled Urologists Really Need to Perform reTUR for all HG Patients?
AUA 2024: Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment: An Analysis of Pivotal Trial and Real-World Data in China
AUA 2024: Can Photodynamic Diagnosis-Guided Biopsy Replace Bladder Mapping Biopsy?
AUA 2024: Long Term Outcomes of Low and Intermediate Risk Bladder Cancer Patients Treated with Transurethral Resection Eligible for Active Surveillance
AUA 2024: Intravesical Instillations in Octogenarian High Grade, Non Muscle-Invasive Bladder Cancer Patients: Could They Offer a Real Survival Advantage?
AUA 2024: Head-to-Head Oncological Outcomes Comparison of Mitomycin C vs BCG Treatment in Intermediate-Risk Non-Muscle Invasive Bladder Cancer Patients
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
